Clinically Inapparent Right Heart Dysfunction is Associated with Reduced Myofilament Force Development in Coronary Artery Disease

Constanze Bening (✉ Bening_C@ukw.de)
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Vima Sales
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Khaled Alhussini
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Dejan Radakovic
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Rodolfo Benitez
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Nodir Madrahimov
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Daniel Keller
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Rainer Leyh
Department of Thoracic and Cardiovascular Surgery, University of Wuerzburg, Wuerzburg, Germany.

Research Article

Keywords: skinned fiber, coronary artery bypass grafting, right heart impairment, pCa

DOI: https://doi.org/10.21203/rs.3.rs-124897/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Right ventricular dysfunction after CABG is associated with poor peri- and postoperative outcomes. We hypothesized that inapparent RV dysfunction in these patients is already associated with pathological changes at the level of myofilaments in concert with altered biomarkers of myocardial remodeling and endothelial dysfunction.

Methods: From 08/2016 to 02/2018, 218 patients scheduled for CABG were divided into two groups (TAPSE \( \geq \)20mm, n=178; TAPSE<20mm, n=40). Baseline serum samples for biomarkers (Galectin,TGFß1,N Acyl-SDMA, Arginine, ADMA and Pentraxin-3), clinical laboratory and transthoracic echocardiographic parameters were evaluated. To examine the myocardial apparatus of the right ventricle intraoperative right auricular tissue was harvested for stepwise skinned fiber force measurements.

Results: Patients with TAPSE <20mm had a higher incidence of DM (55vs34%,p=0.018), preoperative AFib (43vs16%,p=0.000), reduced GFR (67±18vs77±24 ml/min/1.73m2,p=0.013), larger LA area (22±6vs20±5cm2,p=0.005) and reduced LVEF (50vs55 %,p=0.008). Furthermore, higher serum ADMA (0.70±0.13vs0.65±0.15µmol/l, p=0.046) and higher serum Pentraxin-3 levels (3371±1068vs2681±1353pg/dl,p=0.004) were observed in these Patients. Skinned fibre force measurements showed significant lower values at almost every step of calcium concentration (pCa 4.52 to pCa 5.5,p<0.01 and pCa 5.75 to 6.0,p< 0.05). Multivariable analysis revealed DM (OR 2.53 CI1.12-5.73, Euro Score II (OR1.34 CI 1.02-1.78), preoperative AF (OR4.86 CI2.06-11.47), GFR (OR7.72 CI 1.87-31.96), albumin (OR1.56 CI 0.52-2.60), Pentraxin-3 (OR19.68 CI14.13-25.24), depressed LVEF (OR8.61 CI 6.37-10.86), lower force values: (pCa 5.4; OR2.34 CI 0.40-4.29 and pCa 5.2; OR2.00 CI 0.39-3.60) as predictors for clinical inapparent right heart dysfunction.

Conclusions: These preliminary data showed that inapparent right heart dysfunction in CAD is already associated with reduced force development of the contractile apparatus.

Background

Right ventricular dysfunction in patients undergoing coronary artery bypass surgery (CABG) is associated with poor perioperative and postoperative outcomes (1, 2, 3). Identifying patients at risk for impaired right heart function could be helpful in risk-stratification of surgical candidates with symptomatic coronary artery disease (CAD) (3). Due to the complex geometry of the right heart, its functional assessment is cumbersome (4, 5). The ACC/AHA and ESC guidelines recommend TAPSE, for estimating RV global systolic function (5, 6). However, earlier studies providing TAPSE cut-off at < 16 mm yielded low sensitivity in patients with reduced RV, highlighting the potential pitfall of this technique in demonstrating the involvement of intrinsic myocardial force capacity of right ventricular myofilaments (6). Furthermore, underlying remodeling processes occurring in RV of preoperative CABG patients as well as those with reduced right heart function have not been well-defined utilizing prognostic biomarkers. (7).
The relative paucity of translational studies on the relationship between TAPSE, intrinsic myocardial function and biomarkers at the level of the myocardial apparatus in symptomatic CAD patients prior to CABG, contribute to this uncertainty. We hypothesized that patients with impaired evident (TAPSE < 16 mm) and inapparent (TAPSE > 16 mm and < 20 mm) right heart dysfunction may have impaired induced myocardial force values and could be identified with altered levels of biomarkers underlying myocardial remodeling processes. The aim of the study was to provide new insights into the pathophysiology and suggest factors associated with reduced myocardial contractility on the level of the myocardial apparatus for expanded clinical and mechanistic studies.

**Methods**

Two-hundred eighteen patients undergoing elective on pump CABG between August 2016 and February 2018 were enrolled in this study. All patients were informed and gave their written consent to participate. The study was approved by the University Hospital ethics committee (IRB approval: 143/17-sc 6.10.2017). Patients with valve pathologies, reoperations, emergency indications or pulmonary hypertension of any origin were excluded.

All patients received a routine preoperative echocardiographic examination (Philips Epiq 7, Philips Health System, Hamburg, Germany). Measurements and analysis were performed by trained echocardiography technician, blinded to patients. We measured left and right atrial end-systolic areas, systolic pulmonary artery pressure (sPAP), TAPSE, left ventricular ejection fraction (LVEF), according to echocardiographic guidelines for assessment of right heart function (10). We divided the patients in two groups: group 1 with TAPSE values ≥ 20 and group 2 with TAPSE value < 20 mm and compared experimental force values from the right atrial auricle as well as all baseline clinical characteristics among both groups. All data including clinical findings and preoperative medication were recorded pseudonymously in a departmental database. Prior to induction of anesthesia, preoperative routine blood samples were drawn from all patients and immediately sent to the laboratory to be stored at -80 °C.

Preoperative clinical chemistry included creatinine, albumin, glomerular filtration rate (GFR) and N-terminal pro brain natriuretic peptid (NT-proBNP). We performed enzyme-linked immunosorbant assay (ELISA) for the following markers of fibrosis and inflammation, taken from serum blood samples of the patients. All ELISAs were conducted with the ELISA reader Tecan Infinity Pro (Tecan Group Ltd., Switzerland): Galectin, Transforming Growth Factor β (TGFβ), N Acyl- Symmetric Dimethylarginine (N-Acyl-SDMA), Arginine, Asymmetric Dimethylarginine (ADMA) (QuantiKine Elisa, DGD150, R&D Systems, Bio-Techne, Wiesbaden, Germany) and Pentraxin (Pentraxin 3 Human ELISA, RD191477200R, BioVendor, Czech Republic).

**Experimental set-up:**

We measured the calcium-induced force of right atrial skinned human fibers as previously described (8, 9, 10). We resected the RAA for venous cannulation of extracorporal circulation. This RAA tissue was used
for experimental calcium-induced force measurements. Briefly, the intraoperatively resected tissue was transported in ice-cold oxygenated cardioplegic solution, containing BDM (Sigma Aldrich Chemie GmbH, Steinheim, Germany). For the skinning procedure, the trabeculae were excised, immersed in Triton-X solution (Sigma Aldrich Chemie GmbH, Steinheim, Germany) and processed for sarcolemma removal.

The trabeculae were then cut in to small bundles for the experimental cycle. The experimental set-up has been previously described (8, 9, 10). Briefly, the bundles were fixed between two forceps. A force transducer is connected to one of the forceps for recording any calcium-induced length changes. The bundles were then immersed increasing calcium concentrations. The calcium concentration is displayed as logarithmic calcium concentration (pCa), which is a negative decadic logarithm. We started with the lowest calcium concentration at pCa 7.0 and increasing at 6.5, 6.0, 5.75, 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.75, 4.52.

### Statistical Analysis

Demographic variables, comorbidities, blood tests, ventricular function, operative data, 30-day, and mid-term outcomes in patients undergoing elective CABG were compared between patients with TAPSE ≤ 20 vs. ≥ TAPSE. Continuous and categorical variables were compared using t-test and Fisher’s exact test, respectively. Multivariable logistic regression models were constructed to identify factors associated with reduced right heart function (TAPSE ≤ 20 mm). Candidate variables include age, sex, Euro Score II, diabetes mellitus (DM), preoperative AF, glycated haemoglobin (HbA1c), NTPro-BNP, GFR, albumin, ADMA, Pentraxin-3, right end-systolic area, sPAP, TAPSE, left atrial diameter, LVEF, cardiopulmonary bypass (CPB) time, incision-suture time, ventilation time, prolonged ventilation.

Overall survival estimates were obtained by Kaplan-Meier method. The groups were compared with a log-rank test. Cox proportional hazards regression was used to discriminate risk factors associated with time of death. Model assumptions, including proportional hazards assumption, linearity, and normality were evaluated. All estimates are provided with 95% confidence interval (CI). Multiple imputation, analysis and pooling of the results for missing continuous variables were performed reporting mean value of the study cohort for that parameter (missing: 62 [27.3%] for FEV1, 30[13,2%] for NT Pro BNP 29[12,8%] for CRP, 9[4,0%] for GFR, 9[4,0%] for HbA1c, 9[4,0%] for Albumin, 60[26,4%] for Galectin, 50[22,0%] for TGFβ1, 53[23,3%] for N Acyl-SDMA, 60[26.4%] for arginine,56[24.7%] for ADMA, 49[21,6%] for Pentraxin-3, 29[12,8%] for RA area, 29[12,8%] for LA area,17[7,5%] for LVEF, 63[27,8%] for sPAP and a dummy variable was used to indicate replacement of missing data. Appropriate models were selected with appropriate candidate variables included with respect to relevance to right heart failure and missing completely at random assumption. Five imputed datasets were used for efficiency and reproducibility of the results. Cox regression using complete cases, single mean and multiple imputation were performed and compared with patients without missing data. Models including only patients without missing data yielded no significant change in overall results.

Candidate variables considered for the multivariable analyses were those detected by univariate models as having a $p < 0.05$ or suggestive trend toward association ($p = 0.05–0.20$) predictive of abnormal
TAPSE and mortality; retention of variables in the multivariable model was set at $p < 0.05$. To discriminate independent risk factors, multivariable modeling was performed with methods of stepwise selection, with entry/stay criteria of 0.1/0.1 and exclusion of highly intercorrelated, redundant explanatory variables with $r$ values set at $> 0.70$, with TAPSE groups and candidate variables all competing for entry into a final model. The final model included all independent risk factors for reduced right heart function and mortality meeting these criteria. Multivariable linear regression was used to adjust for significant independent variables for reduced right heart function (TAPSE $\leq 20$ mm) and multivariable logistic regression was used to adjust for significant variables for POAF. All estimates are provided with 95% confidence intervals (CI). Probability $p$-values were considered as statistically significant when $p < 0.05$. All analyses were performed using SPSS 25 (IBM; Amonk, New York, USA).

**Clinical Outcomes**

An endpoint of all-cause mortality was considered to be the primary endpoint. Death notification was confirmed by medical record (evidence of life or death).

**Results**

**Patient Baseline and Perioperative Characteristics**

218 patients who underwent elective CABG were evaluated. The age (mean $\pm$ SD) of the patient cohort was $68 \pm 9$ years and 187 (86%) were male. The clinical characteristics of patients are summarized in Table 1.
Table 1
Baseline Characteristics of 218 patients undergoing elective CABG

| Characteristics                  | Total       | Group 1               | Group 2               | P value |
|----------------------------------|-------------|-----------------------|-----------------------|---------|
|                                  | 218 (100%)  | n:178 (82%)           | n: 40 (18%)           |         |
| Age (y, mean ± SD)               | 67.6 ± 9.4  | 67.1 ± 9.5            | 70.0 ± 8.5            | 0.079   |
| Female (n,% )                    | 31 (14.2)   | 24 (13.5)             | 7(17.5)               | 0.465   |
| Height (cm, mean ± SD)           | 172.0 ± 7.4 | 172.0 ± 7.5           | 172.0 ± 6.8           | 0.855   |
| Weight (kg, mean ± SD)           | 87.5 ± 15.8 | 87.3 ± 16.2           | 88.3 ± 14.3           | 0.721   |
| EuroScore II (mean ± SD)         | 1.6 ± 1.2   | 1.4 ± 1.1             | 2.2 ± 1.6             | 0.000   |
| Diabetes Mellitus (n,% )         | 82 (37.6)   | 60 (33.7)             | 22 (55.0)             | 0.018   |
| Hypertension (n,% )              | 188 (86.2)  | 155 (87.1)            | 33 (82.5)             | 0.450   |
| Atrial fibrillation (n,% )       | 45 (20.7)   | 28 (15.8)             | 17 (42.5)             | 0.000   |
| HbA1c (% , mean ± SD)            | 6.2 ± 1.0   | 6.1 ± 1.0             | 6.5 ± 1.2             | 0.020   |
| NTPro-BNP (pg/mL, mean ± SD)     | 964.8 ± 2879.0 | 853.2 ± 2988.4       | 1461.3 ± 2257.4      | 0.129   |
| Creatinine (mg/dL, mean ± SD)    | 1.2 ± 0.7   | 1.1 ± 0.8             | 1.2 ± 0.4             | 0.726   |
| GFR (ml/min/1.73 m$^2$, mean ± SD)| 74.8 ± 23.1 | 76.7 ± 23.8           | 66.7 ± 17.6           | 0.013   |
| Albumin (g/dl, mean ± SD)        | 4.2 ± 0.5   | 4.3 ± 0.5             | 4.1 ± 0.4             | 0.036   |
| Galectin (ng/dL, mean ± SD)      | 10.7 ± 5.4  | 10.6 ± 5.7            | 10.9 ± 4.3            | 0.842   |
| TGFβ1 (pg/mL, mean ± SD)         | 29570.6 ± 68503.3 | 30876.8 ± 75129.3  | 23757.9 ± 21591.2    | 0.633   |
| N Acyl-SDMA (µmol/l, mean ± SD)  | 0.69 ± 0.32 | 0.69 ± 0.34           | 0.73 ± 0.22           | 0.318   |
| Arginin (µmol/l, mean ± SD)      | 92.9 ± 31.5 | 92.4 ± 31.6           | 94.8 ± 31.0           | 0.363   |
| ADMA (µmol/l, mean ± SD)         | 0.66 ± 0.15 | 0.65 ± 0.15           | 0.70 ± 0.13           | 0.046   |
| Pentraxin-3 (pg/dl, mean ± SD)   | 2807.4 ± 1329.2 | 2681.0 ± 1353.4    | 3370.5 ± 1068.4      | 0.004   |
| LA area (cm$^2$ mean ± SD)       | 20.4 ± 5.3  | 19.9 ± 5.0            | 22.4 ± 6.0            | 0.005   |

FEV1: forced expiratory volume; CRP: C-reactive protein. HbA1c: glycated haemoglobin (HbA1c), NTPro-BNP: N-terminal pro brain natriuretic peptide; GFR: glomerular filtration rate; TGF β-1: Transforming Growth Factor β; IL-6: Interleukin-6; N Acyl-SDMA: Symmetric Dimethylarginine; ADMA: Asymmetric Dimethylarginine; RA: right atrial; sPAP: Systolic pulmonary artery pressure; LA: left atrial; LVEF: Left ventricular ejection fraction
| Characteristics | Total   | Group 1 | Group 24 | P value |
|-----------------|---------|---------|----------|---------|
|                 | 218 (100%) | n:178 (82%) | n: 40 (18%) |         |
| TAPSE           | 23.0 ± 4.0 | 24.3 ± 3.1 | 17.3 ± 1.7 | 0.000   |
| LVEF (%)        | 53.7 ± 9.8 | 54.6 ± 9.3 | 49.7 ± 11.2 | 0.008   |

FEV1: forced expiratory volume; CRP: C-reactive protein; HbA1c: glycated haemoglobin (HbA1c); NTPro-BNP: N-terminal pro brain natriuretic peptid; GFR: glomerular filtration rate; TGF ß-1: Transforming Growth Factor ß; IL-6: Interleukin-6; N Acyl-SDMA: Symmetric Dimethylarginine; ADMA: Asymmetric Dimethylarginine; RA: right atrial; sPAP: Systolic pulmonary artery pressure; LA: left atrial; LVEF: Left ventricular ejection fraction

Patients with reduced TAPSE (Group 2) presented with a significant higher EuroScoreII (2.2 ± 1.6 vs. 1.4 ± 1.1, p = 0.000), higher incidence of DM (55%vs34%, p = 0.018), greater prevalence of AF (43%vs16%, p = 0.000), larger LA size (22 ± 6 cm^2 vs 20 ± 5 cm^2, p = 0.005), decreased LVEF (LVEF 50% vs 55%, p = 0.008), reduced preoperative glomerular filtration rates (GFR, MDRD: 66.7 ± 17.60 ml/min/1.73 m^2 vs 76.7 ± 23.8 ml/min/1.73 m^2, p = 0.013), lower preoperative Albumin serum concentrations (4.1 ± 0.4 g/dl vs 4.3 ± 0.5 g/dl, p = 0.036) and higher serum concentrations of Pentraxin-3 (3371 ± 1068 pg/dl vs 2681 ± 1353 pg/dl, p = 0.004) and increased ADMA levels (0.70 ± 0.13 µmol/l vs 0.65 ± 0.15 µmol/l, p = 0.046).

Operative and postoperative data are depicted in Table 2: Median bypass time was significant longer in patients in group 2 (114 (265) minutes vs. 107 (161) minutes, p = 0.009). Furthermore patients developed significant more often POAF (53vs30%, p = .009) and prolonged LOS (mean 13 days vs 11 days, p = .009)
Table 2
Operative and Early and Midterm Outcomes

| Variables                                           | Total   | Group 1  | Group 2  | P value |
|-----------------------------------------------------|---------|----------|----------|---------|
|                                                     | n: 218  | n: 178   | n:40     |         |
|                                                     | (100%)  | (82%)    | (18%)    |         |
| **Intraoperative times**                            |         |          |          |         |
| Cardiopulmonary bypass time (minutes, median IQR)   | 108.0(265.0) | 107.0(161) | 114.0(265.0) | 0.009   |
| Cross Clamp time (minutes, median IQR)              | 81.0(195.0)  | 82.0(195.0) | 79.0(171.0)  | 0.540   |
| Incision-suture time (minutes, median IQR)          | 234.5(388.0) | 235.5(292.0) | 229.5(354.0) | 0.161   |
| **Early outcomes (≤ 30 d)**                         |         |          |          |         |
| Ventilation time (hours,median IQR)                 | 9.3(398.7)  | 9.2(398.7) | 10.8(195.1) | 0.127   |
| Prolonged Ventilation (≥ 12 hours,n %)              | 68(31.2)   | 52(29.2)  | 16(40.0)  | 0.191   |
| Length of stay (days, mean ± SD)                    | 11.4 ± 5.1 | 10.9 ± 3.9 | 13.3 ± 8.3 | 0.009   |
| Postoperative Afib (n, %)                            | 74(33.9)   | 53(29.8)  | 21(52.5)  | 0.009   |
| Discharge and 30-d Mortality (n, %)                 | 2(0.9)     | 2(1.1)    | 0(0.0)    | 1.000   |
| **Mid-term outcomes (>30d)**                         |         |          |          |         |
| All-cause moratlity (>30-d, n, %)                   | 5(2.3)     | 4(2.3)    | 1(2.5)    | 1.000   |

IQR: Interquartile range

Table 3 demonstrates the experimental force measurements at increasing steps of calcium concentrations. Patients with reduced TAPSE had significant lower force values at almost every step of pCa except for the lowest pCa 7.0:0.021 ± 0.014 mN vs 0.023 ± 0.015 mN, p = 0.625) and the second lowest step of pCa 6.5 (0.035 ± 0.017 mN vs 0.042 ± 0.022 mN, p = 0.069). At all other steps of calcium concentration were significant lower in the group with reduced TAPSE.
Table 3
Calcium-induced Force Values of Right atrial Myofilaments in 218 Patients

| Characteristics | Group 1                  | Group 2                  | P value |
|-----------------|--------------------------|--------------------------|---------|
|                 | n: 178 (82%)             | n: 40 (18%)              |         |
| pCa 7.0         | 0.023 ± 0.015 mN         | 0.021 ± 0.014 mN         | 0.625   |
| pCa 6.5         | 0.042 ± 0.022 mN         | 0.035 ± 0.017 mN         | 0.069   |
| pCa 6.0         | 0.148 ± 0.088 mN         | 0.112 ± 0.052 mN         | 0.011   |
| pCa 5.75        | 0.263 ± 0.162 mN         | 0.193 ± 0.111 mN         | 0.010   |
| pCa 5.5         | 0.450 ± 0.242 mN         | 0.330 ± 0.183 mN         | 0.004   |
| pCa 5.4         | 0.567 ± 0.272 mN         | 0.424 ± 0.222 mN         | 0.002   |
| pCa 5.3         | 0.630 ± 0.296 mN         | 0.462 ± 0.246 mN         | 0.001   |
| pCa 5.2         | 0.705 ± 0.326 mN         | 0.521 ± 0.264 mN         | 0.001   |
| pCa 5.1         | 0.763 ± 0.343 mN         | 0.575 ± 0.282 mN         | 0.001   |
| pCa 5.0         | 0.770 ± 0.358 mN         | 0.574 ± 0.092 mN         | 0.001   |
| pCa 4.75        | 0.847 ± 0.375 mN         | 0.642 ± 0.304 mN         | 0.001   |
| pCa 4.52        | 0.834 ± 0.384 mN         | 0.636 ± 0.315 mN         | 0.003   |
| pCa: logarithmic calcium-concentration. |

Independent predictors of reduced TAPSE.

After excluding variables with significant intercorrelation, this analysis yielded 33 candidates for the multivariable model. Higher incidence of DM odds ratio (OR) 2.53;95% CI,1.12 to 5.73), higher EuroScore II (OR, 1.34;95% CI,1.02 to 1.78) greater prevalence of preoperative AF (OR ratio,4.86;95% CI,2.06 to 11.47), decreased GFR (OR, 7.72;95% CI,2.06 to 11.47) and lower albumin level (OR, 1.56;95% CI,0.52 to 2.60), higher level of Pentraxin-3 (OR, 4.2719.68;95% CI,14.58 13 to 1125.5124), poorer LVEF (OR, 8.61;95% CI,6.37 to 10.76) and lower calcium-induced force values: pCa 5.4 (OR, 2.34;95% CI,0.40 to 4.29 and pCa 5.2 (OR 2.00;95% CI,0.40 to 3.60 appear to influence the odds of reduced right heart function, represented by abnormal TAPSE (< 20 mm).

Mid-term survival

Figure 1 depicts Kaplan-Meier survival curve comparing patients with TAPSE < 20 mm (n = 40) and TAPSE ≥ 20 mm (n = 178) undergoing elective CABG procedures.
Overall unadjusted estimated survival at 6, 12, 18 and 24 months was 99%, 98%, 98%, and 95%, respectively. Survival in group 2 was 100%, 97%, 97% and 97%, respectively, and in group 1 it was 98%, 98%, 98% and 95%, respectively. Survival was similar among TAPSE groups ($p = 0.889$).

The mean (± SD) follow-up was 14 ± 6 months in group 2 and 13 ± 6 months in group 1. Follow-up was completed in 98%.

**Effect of Clinical Variables on Survival**

There were 5 patients with events (all-cause death) during follow-up (median, 13 months). Presence of POAF (HR, 42.10; $p = 0.021$), higher EuroScore II (HR, 1.34; $p = 0.016$), and lower GFR (HR, 0.872; $p = 0.004$) were each independently associated with a higher HR for death (See Table 4).

| Variable                  | Hazard Ratio | 95% CI          | P value |
|---------------------------|--------------|-----------------|---------|
| Overall Mortality         | 42.095       | 1.759–10.450    | 0.021   |
| Postoperative Afib        | 1.343        | 1.255–8.940     | 0.016   |
| Higher Euro Score II      | 0.872        | 0.794–0.958     | 0.004   |
| GFR                       | 0.872        | 0.794–0.958     |         |

Ab: Atrial Fibrillation; GFR: glomerular filtration rate

**Discussion**

Our present study found that patients with reduced preoperative right ventricular function (TAPSE < 20 mm) showed significant impairment of the contractile apparatus utilizing our experimental model of skinned human right auricular fibers. A significant reduction in calcium-induced force values was observed at every force step generated by increasing calcium concentration. For TAPSE, cut-off point of < 16 mm according to guidelines, predicted impaired RV function with high specificity but low sensitivity (7). Therefore, we examined patients with a TAPSE of 16 to 20 mm to ensure the presence of impaired RV function, which in turn, may also reflect RV myofilament involvement.

Our data show that experimental force development significantly decreases in patients with moderate to severe RV dysfunction. These results confirm that even in the absence of clinical symptoms, right heart dysfunction appears to be present in elective CABG patients. Thus, this subpopulation of “asymptomatic” surgical candidates may have a priori a greater incidence of developing RV failure. Available evidence does suggest that chronic ischemia of the inferior, lateral LV walls and ventricular septum increase the likelihood of RV dysfunction (11, 12, 13, 14, 15, 16). This might aggravate immediately after CABG, due to the fact that the ventricular septum, which is important for RV function is prone to inadequate myocardial protection in 40–80% of cardiac surgery patients. (11, 12, 13, 14, 15, 16)
Another finding is that DM, preoperative Afib, higher EuroScore II, lower albumin level, decreased GFR, and reduced LVEF were associated with reduced right heart function, which is in concert with literature (17, 18, 19, 20, 21). Our previous study demonstrated that there is a significant force decrease in right auricular myofilaments in patients with type 2 diabetes compared without (9). Similarly, Patschneider et al. showed that DM as well as prediabetes is associated with decreased RV endsystolic and enddiastolic volumes as well as stroke volumes, indicative of early-onset RV impairment prior to symptom onset. (17, 18). Post-translational modification (O-linked β-N-acetylglucosamine modification) in DM patients may have contributed to changes in calcium sensitivity, which is a measure of impaired contractile force development. (9).

Gorter and coworkers demonstrated that Afib is associated with right heart dysfunction as result of decreased RA emptying fraction and reduced RA reservoir strain (19). Similarly, we had earlier demonstrated significant reduced calcium induced force values after CABG were associated with new-onset POAF (10).

Recent studies have described the association of impaired renal function and decreased serum albumin levels in right-sided HF, which may be the result of subclinical remodeling process of the right atrium and ventricle (20, 21). In sum, right ventricular dysfunction is a multifactorial disease with clustered and interactive risk factors, which could be detected at the level of the myofilament apparatus by means of a reduced calcium induced force value capacity.

To date, right-sided HF pathophysiology in symptomatic CHD for CABG remains unknown and there is no ability to determine who is at risk of progression or who will recover after CABG. To overcome these pitfalls, we analyzed a series of candidate markers for fibrosis and inflammation in baseline serum blood samples and correlated these factors with reduced right heart function. Significantly higher normalized concentrations of Pentraxin-3 in patients with reduced TAPSE vs. with normal TAPSE was significantly positively associated with reduced right heart function. Pentraxin-3 is a protein mediator of innate immunity produced by VSMCs and ECs (22) and observed predominantly in patients with impaired diastolic function, metabolic syndrome, myocarditis and chronic HF (23, 24). Regarding indices of RV function, Pentraxin-3 is reported to modify RV adaption with resultant greater RV mass and larger RV end-diastolic volume independent of LV morphologic changes, suggesting a RV-specific relationship (24). We also found ADMA significantly increased in patients with reduced TAPSE. ADMA is an analogue of L-arginine and a naturally occurring product of metabolism found in human circulation (25). Elevated levels of ADMA inhibit NO synthesis, in turn, impair endothelial function and thus promote atherosclerosis. ADMA levels are increased in people with hypercholesterolemia, atherosclerosis, hypertension, chronic heart failure, diabetes mellitus and chronic renal failure (25). A number of studies have reported ADMA as a novel risk marker of cardiovascular disease (25). Increased levels of ADMA have been shown to be the strongest risk predictor, beyond traditional risk factors, of cardiovascular events and all-cause and cardiovascular mortality in CAD (25). Accumulation of ADMA in chronic systolic heart failure was observed to be associated with presence of LV diastolic dysfunction as well as unfavorable pulmonary hemodynamics in patients with idiopathic pulmonary artery hypertension, however a direct association
with decreased right heart function without these comorbidities was not shown thus so far (25, 26). Our findings have revealed that increased ADMA levels, detected in patients with reduced right heart function might be associated with reduced renal function or prevalent DM (traditional risk factors for atherosclerosis). ADMA, in turn, may regulate NO expression in the pathogenesis of atherosclerosis (25). Of importance in symptomatic CAD patients prior to CABG is the relationship of ADMA to RV dysfunction. This possible link remains to be elucidated independent of comorbidities.

In this study, reduced right heart function had no impact on clinical outcome parameters aside from significant longer hospital stay, which is inevitable in patients with reduced right heart function (2). Reduced right heart function did not influence survival in our patient cohort; this might be due to either short follow up of 14 months or the fact that the majority of patients in the reduced TAPSE group belonged to the “grey zone “of right heart dysfunction (TAPSE 17 mm-20 mm)

**Limitations**

Several limitations must be noted. First, the sample size is still too small to draw conclusions concerning predictors for postoperative right heart impairment and follow-up in patients with CAD undergoing CABG procedure. Second, the higher incidence of diabetes and Afib in the group with reduced TAPSE might have also influenced the contractile capacity of the skinned fibers. Third, operator-specific treatment of the tissue samples with possible damage to the trabeculae cannot be excluded, although harvesting protocols were designed with a high degree of standardization. Furthermore in the scientific statement from the American Heart Association on evaluation and management of right-sided heart failure (27) cardiac MRI has become the gold standard for quantitative noninvasive measurement of RV dimensions and EF since cardiac MRI offers 3-dimensional imaging of the entire heart,

However, TAPSE has been established as an easy and fast obtainable screening method for right heart function with good correlation with more sophisticated techniques estimating RV systolic function (radionuclide-derived RV EF or 2D RF EF) (6).

Despite the nature of our study, our analysis may serve as catalyst for future mechanistic and observational studies to define predictors for impaired right heart function in patients with CAD.

**Conclusions**

These preliminary data showed that a TAPSE of < 20 mm is associated with signs of right heart dysfunction at the level of myofilament apparatus. Increased Pentraxin-3 levels were associated with a TAPSE < 20 mm and could help identify patients at risk for right dysfunction immediately after CABG. However, larger studies and longer follow-up are mandatory to confirm our findings and delineate their clinical impact.

**Abbreviations**
Declarations

Ethics approval and consent to participate:

All patients were informed and gave their written consent to participate. The study was approved by the University Wuerzburg Hospital ethics committee (IRB approval: 143/17-sc 6.10.2017). All method were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable
Availability of data and materials:
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests:
The authors declare that they have no competing interests

Funding:
This work was supported by the Comprehensive Heart Failure Centre (CHFC) Wuerzburg (Project Number MO.9)

Author Contribution Statement:
C.B.: Conceptualization, Writing-original draft, Funding acquisition, Methodology, Investigation, Supervision
V.S.: Formal Analysis, Validation, Writing-editing and Review, Visualization
R.B.: Investigation, Data curation
K.A.: Software, Project Administration, Investigation
D.R.: Investigation, Data curation, Writing-editing and Review
N.M.: Investigation, Data curation, Writing-editing and Review
D.K.: Investigation, Data curation, Writing-editing and Review
R.L.: Supervision, Resources, Validation, Writing-editing and Review

Acknowledgements:
We thank Johanna Lesch and Renate Wahn for conducting the experiments.

References
1. Lella LK, Sales VL, Goldsmith Y et al. Reduced Right Ventricular Function Predicts Long-Term Cardiac Re-Hospitalization after Cardiac Surgery. PLoS One. 2015 Jul 21.
2. Chinikar M, Rafiee M, Aghajankhah M et al. Right ventricular dysfunction and associated factors in patients after coronary artery bypass grafting. ARYA Atheroscler. 2019;15:99-105.

3. Maslow AD, Regan MM, Panzica P, Heindel S, Mashikian J, Comunale ME. Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. Anesth Analg. 2002;95:1507-18.

4. Kalkan K, Kalkan F, Aksakal E et al. Assessment of right ventricular dysfunction in patients with mitral stenosis: A speckle tracking study. J Clin Ultrasound. 2019 Dec 3. http://dx.doi.org/10.1002/jcu.22798.

5. Suh YJ, Kim D, Shim CY et al. Tricuspid annular diameter and right ventricular volume on preoperative cardiac CT can predict postoperative right ventricular dysfunction in patients who undergo tricuspid valve surgery. Int J Cardiol. 2019;288:44-50.

6. Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713.

7. Jabagi H, Ruel M, Sun LY. Can Biomarkers Provide Right Ventricular-Specific Prognostication in the Perioperative Setting? J Card Fail. 2019 Sep 17. http://dx.doi.org/10.1016/j.cardfail.2019.09.007.

8. Bening C, Leyh R. Right atrial contractile dynamics are impaired in patients with postcapillary pulmonary hypertension. Exp Ther Med. 2016;12:792-798.

9. Bening C, Alhussini K, Mazalu EA et al. Impact of diabetes mellitus on the contractile properties of the left and right atrial myofilaments. Eur J Cardiothorac Surg. 2018;54:826-831.

10. Bening C, Mazalu EA, Yaqub J et al. Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2019 Feb 28 http://dx.doi.org/10.1016/j.jtcvs.2019.02.068.

11. Tajima M, Nakayama A, Uewaki R, Mahara K, Isobe M, Nagayama M. Right ventricular dysfunction is associated with exercise intolerance and poor prognosis in ischemic heart disease. Heart Vessels. 2019;34:385-392.

12. Sabe MA, Sabe SA, Kusunose K, Flamm SD, Griffin BP, Kwon DH. Predictors and Prognostic Significance of Right Ventricular Ejection Fraction in Patients With Ischemic Cardiomyopathy. Circulation. 2016;134:656-65.

13. Bleasdale RA, Frenneaux MP. Prognostic importance of right ventricular dysfunction. Heart. 2002;88:323-4.

14. Addetia K, Patel AR. Beyond right ventricular size and function: the importance of evaluating the right ventricle's capacity for recovery. Expert Rev Cardiovasc Ther. 2014;12:1269-73

15. Kim J, Di Franco A, Seoane T et al. Right Ventricular Dysfunction Impairs Effort Tolerance Independent of Left Ventricular Function Among Patients Undergoing Exercise Stress Myocardial
16. Allen BS. Myocardial protection: a forgotten modality. Eur J Cardiothorac Surg 2020;57:263-70
17. Patscheider H, Lorbeer R, Auweter S et al. Subclinical changes in MRI-determined right ventricular volumes and function in subjects with prediabetes and diabetes. Eur Radiol. 2018;28:3105-3113.
18. Tadic M, Celic V, Cuspidi C et al. Right heart mechanics in untreated normotensive patients with prediabetes and type 2 diabetes mellitus: a two- and three-dimensional echocardiographic study. J Am Soc Echocardiogr. 2015;28:317-27.
19. Gorter TM, van Melle JP, Rienstra M et al. Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. J Card Fail. 2018;24:177-185.
20. Snipelisky D, Jentzer J, Batal O, Dardari Z, Mathier M. Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension. Clin Cardiol. 2018;41:782-787.
21. Mukherjee M, Sharma K, Madrazo JA, Tedford RJ, Russell SD, Hays AG. Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. Am J Cardiol. 2017;120:274-278.
22. Liu Q, Tu T, Bai Z, Zhou S. Pentraxin 3 as a new biomarker of diastolic dysfunction. Int J Cardiol. 2011;152:106-7
23. Latini R, Gullestad L, Masson S et al. Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012;14:992-9.
24. Zanetti M, Bosutti A, Ferreira C et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9:243-8.
25. Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev. 2010;6:82–90.
26. Kielstein JT, Bode-Böger SM, Hesse G et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005;25:1414-8.
27. Konstam M, Kiernan M, Bernstein D, Bozkurt B, Jacob M, Kapur N, Kociol R, Lewis E, Mehra M, Pagani F, Raval A, Ward C. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation, Volume 137, Issue 20, 15 May 2018, Pages e578-e622.